<table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th></th>
      <th>disease&amp;hallmark</th>
      <th>HGNC</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th>0</th>
      <td>Alzheimer disease/accumulation of reactive oxygen species</td>
      <td>NOS3</td>
    </tr>
    <tr>
      <th>1</th>
      <td>Alzheimer disease/changes in the extracellular matrix structure</td>
      <td>ADAM10</td>
    </tr>
    <tr>
      <th>2</th>
      <td>Alzheimer disease/degradation of proteolytic systems</td>
      <td>PLAU,PSEN1,ADAM10,BLMH,ACE</td>
    </tr>
    <tr>
      <th>3</th>
      <td>Alzheimer disease/impairment of the mitochondrial integrity and biogenesis</td>
      <td>NOS3</td>
    </tr>
    <tr>
      <th>4</th>
      <td>Alzheimer disease/intercellular communication impairment</td>
      <td>APOE,ADAM10</td>
    </tr>
    <tr>
      <th>5</th>
      <td>Alzheimer disease/stem cell exhaustion</td>
      <td>A2M,ACE</td>
    </tr>
    <tr>
      <th>6</th>
      <td>Alzheimer disease/sterile inflammation</td>
      <td>A2M</td>
    </tr>
    <tr>
      <th>7</th>
      <td>Amyotrophic lateral sclerosis/accumulation of reactive oxygen species</td>
      <td>SOD1</td>
    </tr>
    <tr>
      <th>8</th>
      <td>Amyotrophic lateral sclerosis/degradation of proteolytic systems</td>
      <td>VCP,SQSTM1</td>
    </tr>
    <tr>
      <th>9</th>
      <td>Amyotrophic lateral sclerosis/impairment of the mitochondrial integrity and biogenesis</td>
      <td>SQSTM1</td>
    </tr>
    <tr>
      <th>10</th>
      <td>Amyotrophic lateral sclerosis/intercellular communication impairment</td>
      <td>HNRNPA1</td>
    </tr>
    <tr>
      <th>11</th>
      <td>Amyotrophic lateral sclerosis/nuclear DNA instability</td>
      <td>VCP</td>
    </tr>
    <tr>
      <th>12</th>
      <td>Amyotrophic lateral sclerosis/sterile inflammation</td>
      <td>TBK1</td>
    </tr>
    <tr>
      <th>13</th>
      <td>Amyotrophic lateral sclerosis/transcriptional alterations</td>
      <td>SQSTM1,FUS</td>
    </tr>
    <tr>
      <th>14</th>
      <td>Bleeding disorder, platelet-type/INS/IGF-1 pathway dysregulation</td>
      <td>ITGB3</td>
    </tr>
    <tr>
      <th>15</th>
      <td>Bleeding disorder, platelet-type/degradation of proteolytic systems</td>
      <td>PLAU</td>
    </tr>
    <tr>
      <th>16</th>
      <td>Bleeding disorder, platelet-type/sterile inflammation</td>
      <td>TBXA2R</td>
    </tr>
    <tr>
      <th>17</th>
      <td>Breast cancer/INS/IGF-1 pathway dysregulation</td>
      <td>AKT1,PIK3CA</td>
    </tr>
    <tr>
      <th>18</th>
      <td>Breast cancer/TOR pathway dysregulation</td>
      <td>ATM,AKT1,PIK3CA</td>
    </tr>
    <tr>
      <th>19</th>
      <td>Breast cancer/accumulation of reactive oxygen species</td>
      <td>TP53</td>
    </tr>
    <tr>
      <th>20</th>
      <td>Breast cancer/alterations in DNA methylation</td>
      <td>BRCA1,PPM1D,PIK3CA</td>
    </tr>
    <tr>
      <th>21</th>
      <td>Breast cancer/alterations in histone modifications</td>
      <td>ATM,BRCA1,BRCA2,RAD51</td>
    </tr>
    <tr>
      <th>22</th>
      <td>Breast cancer/chromatin remodeling</td>
      <td>TP53,ESR1,PPM1D</td>
    </tr>
    <tr>
      <th>23</th>
      <td>Breast cancer/degradation of proteolytic systems</td>
      <td>AKT1,BRCA1</td>
    </tr>
    <tr>
      <th>24</th>
      <td>Breast cancer/impairment of the mitochondrial integrity and biogenesis</td>
      <td>TP53,AKT1</td>
    </tr>
    <tr>
      <th>25</th>
      <td>Breast cancer/intercellular communication impairment</td>
      <td>TP53,PPM1D,KRAS</td>
    </tr>
    <tr>
      <th>26</th>
      <td>Breast cancer/mitochondrial DNA instability</td>
      <td>TP53</td>
    </tr>
    <tr>
      <th>27</th>
      <td>Breast cancer/nuclear DNA instability</td>
      <td>TP53,ATM,NBN,BRCA1,BRCA2,RAD51</td>
    </tr>
    <tr>
      <th>28</th>
      <td>Breast cancer/senescent cells accumulation</td>
      <td>TP53,ATM,BRCA2</td>
    </tr>
    <tr>
      <th>29</th>
      <td>Breast cancer/stem cell exhaustion</td>
      <td>TP53,ESR1</td>
    </tr>
    <tr>
      <th>30</th>
      <td>Breast cancer/sterile inflammation</td>
      <td>AKT1</td>
    </tr>
    <tr>
      <th>31</th>
      <td>Breast cancer/telomere attrition</td>
      <td>ATM,NBN,BRCA2,RAD51</td>
    </tr>
    <tr>
      <th>32</th>
      <td>Breast cancer/transcriptional alterations</td>
      <td>TP53,ESR1</td>
    </tr>
    <tr>
      <th>33</th>
      <td>Cardiac arrhythmia/intercellular communication impairment</td>
      <td>ANK2,AKAP9,CACNA1C,CACNB2</td>
    </tr>
    <tr>
      <th>34</th>
      <td>Cataract/degradation of proteolytic systems</td>
      <td>WFS1</td>
    </tr>
    <tr>
      <th>35</th>
      <td>Cataract/transcriptional alterations</td>
      <td>MAF</td>
    </tr>
    <tr>
      <th>36</th>
      <td>Charcot-marie-tooth disease/accumulation of reactive oxygen species</td>
      <td>AIFM1,SURF1</td>
    </tr>
    <tr>
      <th>37</th>
      <td>Charcot-marie-tooth disease/chromatin remodeling</td>
      <td>LMNA</td>
    </tr>
    <tr>
      <th>38</th>
      <td>Charcot-marie-tooth disease/degradation of proteolytic systems</td>
      <td>VCP</td>
    </tr>
    <tr>
      <th>39</th>
      <td>Charcot-marie-tooth disease/intercellular communication impairment</td>
      <td>AIFM1,PMP22,KIF1B</td>
    </tr>
    <tr>
      <th>40</th>
      <td>Charcot-marie-tooth disease/nuclear DNA instability</td>
      <td>LMNA,VCP,AIFM1</td>
    </tr>
    <tr>
      <th>41</th>
      <td>Charcot-marie-tooth disease/nuclear architecture impairment</td>
      <td>LMNA</td>
    </tr>
    <tr>
      <th>42</th>
      <td>Charcot-marie-tooth disease/senescent cells accumulation</td>
      <td>LMNA</td>
    </tr>
    <tr>
      <th>43</th>
      <td>Colorectal cancer/INS/IGF-1 pathway dysregulation</td>
      <td>AKT1,PIK3CA,APC</td>
    </tr>
    <tr>
      <th>44</th>
      <td>Colorectal cancer/TOR pathway dysregulation</td>
      <td>AKT1,PIK3CA</td>
    </tr>
    <tr>
      <th>45</th>
      <td>Colorectal cancer/accumulation of reactive oxygen species</td>
      <td>TP53,MT-CO1</td>
    </tr>
    <tr>
      <th>46</th>
      <td>Colorectal cancer/alterations in DNA methylation</td>
      <td>PIK3CA</td>
    </tr>
    <tr>
      <th>47</th>
      <td>Colorectal cancer/alterations in histone modifications</td>
      <td>EP300</td>
    </tr>
    <tr>
      <th>48</th>
      <td>Colorectal cancer/chromatin remodeling</td>
      <td>TP53,EP300</td>
    </tr>
    <tr>
      <th>49</th>
      <td>Colorectal cancer/degradation of proteolytic systems</td>
      <td>AKT1,CTNNB1,APC</td>
    </tr>
    <tr>
      <th>50</th>
      <td>Colorectal cancer/impairment of the mitochondrial integrity and biogenesis</td>
      <td>TP53,AKT1,BAX</td>
    </tr>
    <tr>
      <th>51</th>
      <td>Colorectal cancer/intercellular communication impairment</td>
      <td>TP53,CTNNB1,FGFR3</td>
    </tr>
    <tr>
      <th>52</th>
      <td>Colorectal cancer/mitochondrial DNA instability</td>
      <td>TP53</td>
    </tr>
    <tr>
      <th>53</th>
      <td>Colorectal cancer/nuclear DNA instability</td>
      <td>TP53,BUB1B,MLH3</td>
    </tr>
    <tr>
      <th>54</th>
      <td>Colorectal cancer/senescent cells accumulation</td>
      <td>TP53</td>
    </tr>
    <tr>
      <th>55</th>
      <td>Colorectal cancer/stem cell exhaustion</td>
      <td>TP53,CTNNB1,BRAF</td>
    </tr>
    <tr>
      <th>56</th>
      <td>Colorectal cancer/sterile inflammation</td>
      <td>AKT1,TLR4,TLR2</td>
    </tr>
    <tr>
      <th>57</th>
      <td>Colorectal cancer/transcriptional alterations</td>
      <td>TP53,EP300,CTNNB1</td>
    </tr>
    <tr>
      <th>58</th>
      <td>Diabetes mellitus/INS/IGF-1 pathway dysregulation</td>
      <td>INS,IRS1,PTPN1,IRS2,INSR,AKT2</td>
    </tr>
    <tr>
      <th>59</th>
      <td>Diabetes mellitus/degradation of proteolytic systems</td>
      <td>WFS1</td>
    </tr>
    <tr>
      <th>60</th>
      <td>Diabetes mellitus/intercellular communication impairment</td>
      <td>INS</td>
    </tr>
    <tr>
      <th>61</th>
      <td>Diabetes mellitus/sterile inflammation</td>
      <td>INS,IL6</td>
    </tr>
    <tr>
      <th>62</th>
      <td>Diabetes mellitus/transcriptional alterations</td>
      <td>PPARG,HNF4A</td>
    </tr>
    <tr>
      <th>63</th>
      <td>Dilated cardiomyopathy/changes in the extracellular matrix structure</td>
      <td>LAMA4</td>
    </tr>
    <tr>
      <th>64</th>
      <td>Dilated cardiomyopathy/chromatin remodeling</td>
      <td>LMNA,GATAD1</td>
    </tr>
    <tr>
      <th>65</th>
      <td>Dilated cardiomyopathy/degradation of proteolytic systems</td>
      <td>PSEN1</td>
    </tr>
    <tr>
      <th>66</th>
      <td>Dilated cardiomyopathy/nuclear DNA instability</td>
      <td>LMNA</td>
    </tr>
    <tr>
      <th>67</th>
      <td>Dilated cardiomyopathy/nuclear architecture impairment</td>
      <td>LMNA</td>
    </tr>
    <tr>
      <th>68</th>
      <td>Dilated cardiomyopathy/senescent cells accumulation</td>
      <td>LMNA</td>
    </tr>
    <tr>
      <th>69</th>
      <td>Fanconi anemia/accumulation of reactive oxygen species</td>
      <td>FANCC</td>
    </tr>
    <tr>
      <th>70</th>
      <td>Fanconi anemia/alterations in DNA methylation</td>
      <td>BRCA1</td>
    </tr>
    <tr>
      <th>71</th>
      <td>Fanconi anemia/alterations in histone modifications</td>
      <td>BRCA1,BRCA2</td>
    </tr>
    <tr>
      <th>72</th>
      <td>Fanconi anemia/degradation of proteolytic systems</td>
      <td>BRCA1</td>
    </tr>
    <tr>
      <th>73</th>
      <td>Fanconi anemia/impairment of the mitochondrial integrity and biogenesis</td>
      <td>FANCG</td>
    </tr>
    <tr>
      <th>74</th>
      <td>Fanconi anemia/nuclear DNA instability</td>
      <td>BRCA1,BRCA2,ERCC4,FANCG,FANCL,FANCC</td>
    </tr>
    <tr>
      <th>75</th>
      <td>Fanconi anemia/senescent cells accumulation</td>
      <td>BRCA2</td>
    </tr>
    <tr>
      <th>76</th>
      <td>Fanconi anemia/stem cell exhaustion</td>
      <td>FANCC</td>
    </tr>
    <tr>
      <th>77</th>
      <td>Fanconi anemia/telomere attrition</td>
      <td>BRCA2,ERCC4</td>
    </tr>
    <tr>
      <th>78</th>
      <td>Gastric cancer/INS/IGF-1 pathway dysregulation</td>
      <td>PIK3CA,APC</td>
    </tr>
    <tr>
      <th>79</th>
      <td>Gastric cancer/TOR pathway dysregulation</td>
      <td>PIK3CA</td>
    </tr>
    <tr>
      <th>80</th>
      <td>Gastric cancer/alterations in DNA methylation</td>
      <td>PIK3CA</td>
    </tr>
    <tr>
      <th>81</th>
      <td>Gastric cancer/degradation of proteolytic systems</td>
      <td>APC,CASP10</td>
    </tr>
    <tr>
      <th>82</th>
      <td>Gastric cancer/intercellular communication impairment</td>
      <td>FGFR2,KRAS</td>
    </tr>
    <tr>
      <th>83</th>
      <td>Gastric cancer/stem cell exhaustion</td>
      <td>FGFR2</td>
    </tr>
    <tr>
      <th>84</th>
      <td>Gastrointestinal stromal tumor/accumulation of reactive oxygen species</td>
      <td>SDHC,MTHFR,MTRR,SDHB</td>
    </tr>
    <tr>
      <th>85</th>
      <td>Gastrointestinal stromal tumor/alterations in DNA methylation</td>
      <td>MTRR</td>
    </tr>
    <tr>
      <th>86</th>
      <td>Gastrointestinal stromal tumor/chromatin remodeling</td>
      <td>MTHFR</td>
    </tr>
    <tr>
      <th>87</th>
      <td>Gastrointestinal stromal tumor/intercellular communication impairment</td>
      <td>FOLR1</td>
    </tr>
    <tr>
      <th>88</th>
      <td>Glioma/accumulation of reactive oxygen species</td>
      <td>TP53,IDH1</td>
    </tr>
    <tr>
      <th>89</th>
      <td>Glioma/alterations in histone modifications</td>
      <td>BRCA2</td>
    </tr>
    <tr>
      <th>90</th>
      <td>Glioma/chromatin remodeling</td>
      <td>TP53</td>
    </tr>
    <tr>
      <th>91</th>
      <td>Glioma/impairment of the mitochondrial integrity and biogenesis</td>
      <td>TP53</td>
    </tr>
    <tr>
      <th>92</th>
      <td>Glioma/intercellular communication impairment</td>
      <td>TP53,PTEN</td>
    </tr>
    <tr>
      <th>93</th>
      <td>Glioma/mitochondrial DNA instability</td>
      <td>TP53</td>
    </tr>
    <tr>
      <th>94</th>
      <td>Glioma/nuclear DNA instability</td>
      <td>TP53,BRCA2</td>
    </tr>
    <tr>
      <th>95</th>
      <td>Glioma/senescent cells accumulation</td>
      <td>TP53,PTEN,BRCA2</td>
    </tr>
    <tr>
      <th>96</th>
      <td>Glioma/stem cell exhaustion</td>
      <td>TP53</td>
    </tr>
    <tr>
      <th>97</th>
      <td>Glioma/telomere attrition</td>
      <td>BRCA2</td>
    </tr>
    <tr>
      <th>98</th>
      <td>Glioma/transcriptional alterations</td>
      <td>TP53,PPARG</td>
    </tr>
    <tr>
      <th>99</th>
      <td>Hemolytic uremic syndrome/degradation of proteolytic systems</td>
      <td>CFB,CFH</td>
    </tr>
    <tr>
      <th>100</th>
      <td>Hemolytic uremic syndrome/sterile inflammation</td>
      <td>C3,C3AR1</td>
    </tr>
    <tr>
      <th>101</th>
      <td>Hepatocellular carcinoma/INS/IGF-1 pathway dysregulation</td>
      <td>PIK3CA,APC,IGF2R</td>
    </tr>
    <tr>
      <th>102</th>
      <td>Hepatocellular carcinoma/TOR pathway dysregulation</td>
      <td>PIK3CA</td>
    </tr>
    <tr>
      <th>103</th>
      <td>Hepatocellular carcinoma/accumulation of reactive oxygen species</td>
      <td>TP53</td>
    </tr>
    <tr>
      <th>104</th>
      <td>Hepatocellular carcinoma/alterations in DNA methylation</td>
      <td>PIK3CA</td>
    </tr>
    <tr>
      <th>105</th>
      <td>Hepatocellular carcinoma/chromatin remodeling</td>
      <td>TP53</td>
    </tr>
    <tr>
      <th>106</th>
      <td>Hepatocellular carcinoma/degradation of proteolytic systems</td>
      <td>CTNNB1,APC</td>
    </tr>
    <tr>
      <th>107</th>
      <td>Hepatocellular carcinoma/impairment of the mitochondrial integrity and biogenesis</td>
      <td>TP53</td>
    </tr>
    <tr>
      <th>108</th>
      <td>Hepatocellular carcinoma/intercellular communication impairment</td>
      <td>TP53,CTNNB1</td>
    </tr>
    <tr>
      <th>109</th>
      <td>Hepatocellular carcinoma/mitochondrial DNA instability</td>
      <td>TP53</td>
    </tr>
    <tr>
      <th>110</th>
      <td>Hepatocellular carcinoma/nuclear DNA instability</td>
      <td>TP53</td>
    </tr>
    <tr>
      <th>111</th>
      <td>Hepatocellular carcinoma/senescent cells accumulation</td>
      <td>TP53</td>
    </tr>
    <tr>
      <th>112</th>
      <td>Hepatocellular carcinoma/stem cell exhaustion</td>
      <td>TP53,CTNNB1</td>
    </tr>
    <tr>
      <th>113</th>
      <td>Hepatocellular carcinoma/transcriptional alterations</td>
      <td>TP53,CTNNB1</td>
    </tr>
    <tr>
      <th>114</th>
      <td>Hirschsprung disease/accumulation of reactive oxygen species</td>
      <td>DPYD</td>
    </tr>
    <tr>
      <th>115</th>
      <td>Hirschsprung disease/alterations in histone modifications</td>
      <td>CREBBP</td>
    </tr>
    <tr>
      <th>116</th>
      <td>Hirschsprung disease/changes in the extracellular matrix structure</td>
      <td>FBN1</td>
    </tr>
    <tr>
      <th>117</th>
      <td>Hirschsprung disease/degradation of proteolytic systems</td>
      <td>PLAU,RET</td>
    </tr>
    <tr>
      <th>118</th>
      <td>Hirschsprung disease/stem cell exhaustion</td>
      <td>ZHX2</td>
    </tr>
    <tr>
      <th>119</th>
      <td>Hirschsprung disease/transcriptional alterations</td>
      <td>CREBBP</td>
    </tr>
    <tr>
      <th>120</th>
      <td>Leigh syndrome/accumulation of reactive oxygen species</td>
      <td>NDUFA9,SURF1,NDUFS3,NDUFS4</td>
    </tr>
    <tr>
      <th>121</th>
      <td>Leigh syndrome/impairment of the mitochondrial integrity and biogenesis</td>
      <td>BCS1L,COX10</td>
    </tr>
    <tr>
      <th>122</th>
      <td>Leukemia, acute myeloid/alterations in histone modifications</td>
      <td>JAK2</td>
    </tr>
    <tr>
      <th>123</th>
      <td>Leukemia, acute myeloid/chromatin remodeling</td>
      <td>NPM1</td>
    </tr>
    <tr>
      <th>124</th>
      <td>Leukemia, acute myeloid/impairment of the mitochondrial integrity and biogenesis</td>
      <td>TERT,CEBPA</td>
    </tr>
    <tr>
      <th>125</th>
      <td>Leukemia, acute myeloid/intercellular communication impairment</td>
      <td>KRAS</td>
    </tr>
    <tr>
      <th>126</th>
      <td>Leukemia, acute myeloid/nuclear DNA instability</td>
      <td>TERT,NPM1</td>
    </tr>
    <tr>
      <th>127</th>
      <td>Leukemia, acute myeloid/senescent cells accumulation</td>
      <td>TERT,NPM1</td>
    </tr>
    <tr>
      <th>128</th>
      <td>Leukemia, acute myeloid/telomere attrition</td>
      <td>TERT</td>
    </tr>
    <tr>
      <th>129</th>
      <td>Leukemia, acute myeloid/transcriptional alterations</td>
      <td>JAK2,MLF1</td>
    </tr>
    <tr>
      <th>130</th>
      <td>Lung cancer/INS/IGF-1 pathway dysregulation</td>
      <td>PIK3CA</td>
    </tr>
    <tr>
      <th>131</th>
      <td>Lung cancer/TOR pathway dysregulation</td>
      <td>PIK3CA</td>
    </tr>
    <tr>
      <th>132</th>
      <td>Lung cancer/accumulation of reactive oxygen species</td>
      <td>CYP2A6</td>
    </tr>
    <tr>
      <th>133</th>
      <td>Lung cancer/alterations in DNA methylation</td>
      <td>PIK3CA</td>
    </tr>
    <tr>
      <th>134</th>
      <td>Lung cancer/intercellular communication impairment</td>
      <td>KRAS</td>
    </tr>
    <tr>
      <th>135</th>
      <td>Lung cancer/stem cell exhaustion</td>
      <td>BRAF</td>
    </tr>
    <tr>
      <th>136</th>
      <td>Macular degeneration, age-related/changes in the extracellular matrix structure</td>
      <td>FBLN5</td>
    </tr>
    <tr>
      <th>137</th>
      <td>Macular degeneration, age-related/degradation of proteolytic systems</td>
      <td>HTRA1,C2,CFB,CFH</td>
    </tr>
    <tr>
      <th>138</th>
      <td>Macular degeneration, age-related/intercellular communication impairment</td>
      <td>APOE,CX3CR1</td>
    </tr>
    <tr>
      <th>139</th>
      <td>Macular degeneration, age-related/sterile inflammation</td>
      <td>C3,TLR4</td>
    </tr>
    <tr>
      <th>140</th>
      <td>Malaria, susceptibility to/accumulation of reactive oxygen species</td>
      <td>HBB,G6PD</td>
    </tr>
    <tr>
      <th>141</th>
      <td>Malaria, susceptibility to/sterile inflammation</td>
      <td>TNF,TIRAP</td>
    </tr>
    <tr>
      <th>142</th>
      <td>Mental retardation, autosomal dominant/alterations in DNA methylation</td>
      <td>EHMT1</td>
    </tr>
    <tr>
      <th>143</th>
      <td>Mental retardation, autosomal dominant/alterations in histone modifications</td>
      <td>DYRK1A,EHMT1</td>
    </tr>
    <tr>
      <th>144</th>
      <td>Mental retardation, autosomal dominant/chromatin remodeling</td>
      <td>EHMT1,SMARCA4,SMARCE1</td>
    </tr>
    <tr>
      <th>145</th>
      <td>Mental retardation, autosomal dominant/degradation of proteolytic systems</td>
      <td>CTNNB1</td>
    </tr>
    <tr>
      <th>146</th>
      <td>Mental retardation, autosomal dominant/intercellular communication impairment</td>
      <td>CTNNB1</td>
    </tr>
    <tr>
      <th>147</th>
      <td>Mental retardation, autosomal dominant/nuclear DNA instability</td>
      <td>PPP2R1A</td>
    </tr>
    <tr>
      <th>148</th>
      <td>Mental retardation, autosomal dominant/stem cell exhaustion</td>
      <td>CTNNB1</td>
    </tr>
    <tr>
      <th>149</th>
      <td>Mental retardation, autosomal dominant/transcriptional alterations</td>
      <td>CTNNB1,DEAF1</td>
    </tr>
    <tr>
      <th>150</th>
      <td>Myocardial infarction, susceptibility to/INS/IGF-1 pathway dysregulation</td>
      <td>ITGB3</td>
    </tr>
    <tr>
      <th>151</th>
      <td>Myocardial infarction, susceptibility to/accumulation of reactive oxygen species</td>
      <td>GCLC</td>
    </tr>
    <tr>
      <th>152</th>
      <td>Myocardial infarction, susceptibility to/chromatin remodeling</td>
      <td>ESR1</td>
    </tr>
    <tr>
      <th>153</th>
      <td>Myocardial infarction, susceptibility to/degradation of proteolytic systems</td>
      <td>LRP8,ACE</td>
    </tr>
    <tr>
      <th>154</th>
      <td>Myocardial infarction, susceptibility to/impairment of the mitochondrial integrity and biogenesis</td>
      <td>GCLC,GCLM</td>
    </tr>
    <tr>
      <th>155</th>
      <td>Myocardial infarction, susceptibility to/intercellular communication impairment</td>
      <td>LRP8</td>
    </tr>
    <tr>
      <th>156</th>
      <td>Myocardial infarction, susceptibility to/stem cell exhaustion</td>
      <td>ESR1,ACE</td>
    </tr>
    <tr>
      <th>157</th>
      <td>Myocardial infarction, susceptibility to/transcriptional alterations</td>
      <td>ESR1</td>
    </tr>
    <tr>
      <th>158</th>
      <td>Obesity/AMPK pathway dysregulation</td>
      <td>ADRB2</td>
    </tr>
    <tr>
      <th>159</th>
      <td>Obesity/transcriptional alterations</td>
      <td>PPARG,ADRB2</td>
    </tr>
    <tr>
      <th>160</th>
      <td>Parkinson disease/accumulation of reactive oxygen species</td>
      <td>PARK7,SNCA</td>
    </tr>
    <tr>
      <th>161</th>
      <td>Parkinson disease/alterations in histone modifications</td>
      <td>PARK7</td>
    </tr>
    <tr>
      <th>162</th>
      <td>Parkinson disease/degradation of proteolytic systems</td>
      <td>UCHL1,HTRA2,PARK7</td>
    </tr>
    <tr>
      <th>163</th>
      <td>Parkinson disease/impairment of the mitochondrial integrity and biogenesis</td>
      <td>MAPT,HTRA2,PARK7,SNCA</td>
    </tr>
    <tr>
      <th>164</th>
      <td>Parkinson disease/intercellular communication impairment</td>
      <td>UCHL1,MAPT,SNCA,NR4A2</td>
    </tr>
    <tr>
      <th>165</th>
      <td>Parkinson disease/nuclear DNA instability</td>
      <td>PARK7</td>
    </tr>
    <tr>
      <th>166</th>
      <td>Parkinson disease/sterile inflammation</td>
      <td>PARK7</td>
    </tr>
    <tr>
      <th>167</th>
      <td>Parkinson disease/transcriptional alterations</td>
      <td>TBP,NR4A2</td>
    </tr>
    <tr>
      <th>168</th>
      <td>Prostate cancer/INS/IGF-1 pathway dysregulation</td>
      <td>AR</td>
    </tr>
    <tr>
      <th>169</th>
      <td>Prostate cancer/alterations in histone modifications</td>
      <td>BRCA2</td>
    </tr>
    <tr>
      <th>170</th>
      <td>Prostate cancer/intercellular communication impairment</td>
      <td>PTEN,AR</td>
    </tr>
    <tr>
      <th>171</th>
      <td>Prostate cancer/nuclear DNA instability</td>
      <td>BRCA2</td>
    </tr>
    <tr>
      <th>172</th>
      <td>Prostate cancer/senescent cells accumulation</td>
      <td>PTEN,BRCA2</td>
    </tr>
    <tr>
      <th>173</th>
      <td>Prostate cancer/telomere attrition</td>
      <td>BRCA2</td>
    </tr>
    <tr>
      <th>174</th>
      <td>Prostate cancer/transcriptional alterations</td>
      <td>AR</td>
    </tr>
    <tr>
      <th>175</th>
      <td>Retinitis pigmentosa/accumulation of reactive oxygen species</td>
      <td>CYGB</td>
    </tr>
    <tr>
      <th>176</th>
      <td>Retinitis pigmentosa/degradation of proteolytic systems</td>
      <td>TOPORS</td>
    </tr>
    <tr>
      <th>177</th>
      <td>Retinitis pigmentosa/transcriptional alterations</td>
      <td>TOPORS</td>
    </tr>
    <tr>
      <th>178</th>
      <td>Schizophrenia/INS/IGF-1 pathway dysregulation</td>
      <td>AKT1</td>
    </tr>
    <tr>
      <th>179</th>
      <td>Schizophrenia/TOR pathway dysregulation</td>
      <td>AKT1</td>
    </tr>
    <tr>
      <th>180</th>
      <td>Schizophrenia/accumulation of reactive oxygen species</td>
      <td>MTHFR</td>
    </tr>
    <tr>
      <th>181</th>
      <td>Schizophrenia/chromatin remodeling</td>
      <td>MTHFR</td>
    </tr>
    <tr>
      <th>182</th>
      <td>Schizophrenia/degradation of proteolytic systems</td>
      <td>AKT1</td>
    </tr>
    <tr>
      <th>183</th>
      <td>Schizophrenia/impairment of the mitochondrial integrity and biogenesis</td>
      <td>AKT1</td>
    </tr>
    <tr>
      <th>184</th>
      <td>Schizophrenia/intercellular communication impairment</td>
      <td>COMT,HTR2A,SYN2</td>
    </tr>
    <tr>
      <th>185</th>
      <td>Schizophrenia/sterile inflammation</td>
      <td>AKT1</td>
    </tr>
    <tr>
      <th>186</th>
      <td>Spastic paraplegia/impairment of proteins folding and stability</td>
      <td>HSPD1</td>
    </tr>
    <tr>
      <th>187</th>
      <td>Spastic paraplegia/impairment of the mitochondrial integrity and biogenesis</td>
      <td>HSPD1</td>
    </tr>
    <tr>
      <th>188</th>
      <td>Spastic paraplegia/intercellular communication impairment</td>
      <td>PLP1</td>
    </tr>
    <tr>
      <th>189</th>
      <td>Spastic paraplegia/sterile inflammation</td>
      <td>PLP1</td>
    </tr>
    <tr>
      <th>190</th>
      <td>Spinocerebellar ataxia/intercellular communication impairment</td>
      <td>CACNA1A,PRKCG</td>
    </tr>
    <tr>
      <th>191</th>
      <td>Spinocerebellar ataxia/transcriptional alterations</td>
      <td>TBP</td>
    </tr>
  </tbody>
</table>